Preparation method based on recombinant III-type collagen

Through genetic engineering, the recombination of human tri-collagen is solved, and the problem that natural collagen cannot be absorbed by the skin and triggers rejection reactions is achieved, the biocompatibility and functionality of recombinant tri-collagen is enhanced, and skin cells are enhanced. Activity and healing ability reduces spots and relaxation.

CN118878664AInactive Publication Date: 2024-11-01SHAANXI ORIENTAL BLUE OCEAN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202410967080.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Natural three-type collagen cannot be directly absorbed and utilized by the skin, and non-human homologous collagen may trigger rejection and allergic reactions, which cannot effectively supplement skin collagen, resulting in skin sagging, increasing wrinkles and a decrease in wound healing ability.

Method used

Through genetic engineering technology, optimize the recombination of human tri-collagen, design and synthesize gene fragments, construct expression vectors, induce protein expression and purification, obtain recombinant tri-collagen, conduct quality detection and functional testing to ensure its biocompatibility and Low rejection reaction.

Benefits of technology

Recombinant three-type collagen can enhance fibroblast activity, promote cell metabolism, reduce oxidative stress, promote wound healing, inhibit collagen degradation, enhance skin elasticity and gloss, and reduce spot formation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118878664A_ABST
    Figure CN118878664A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of recombinant three-type collagen preparation, and particularly discloses a recombinant three-type collagen-based preparation method, which comprises the following steps: S1, synthesizing a gene segment, S2, constructing an expression vector, S3, carrying out protein expression, S4, carrying out protein extraction and purification, and S5, carrying out quality detection and confirmation. The recombinant three-type collagen can enhance the activity of fibroblasts and promote metabolism of cells, can remove oxygen free radicals ROS, reduces damage of oxidative stress to cells, protects skin cells from oxidative damage by reducing the ROS level, reduces skin pigmentation and stain formation caused by free radicals, and has the effects of preventing and treating the skin aging and the like. The recombinant three-type collagen can specifically bind with integrin and promote proliferation of fibroblasts and wound healing, and the recombinant three-type collagen can specifically bind with integrin, activate downstream signal channels, promote proliferation and migration of fibroblasts, promote proliferation of fibroblasts and synthesis of collagen and accelerate healing of skin wounds.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of recombinant type III collagen preparation, and specifically relates to a preparation method based on recombinant type III collagen. Background Art

[0002] Type III collagen is an extracellular collagen of human skin, mainly distributed in the dermis, and plays a vital role in maintaining skin elasticity and radiance. However, natural type III collagen cannot be directly absorbed and utilized by the skin. It needs to be converted by the human body before it can be converted into a small amount of collagen required by the skin, which is far from meeting the skin's demand for collagen. In addition, since non-human homologous collagen is easily blocked by skin immune cells, it may cause rejection allergic reactions.

[0003] In the field of skin health and beauty, collagen has always been regarded as a key factor in maintaining skin elasticity and youthfulness. With age and the influence of the external environment, collagen in the skin is gradually lost, resulting in sagging skin, increased wrinkles and decreased wound healing ability. Therefore, finding a method that can effectively supplement and enhance the activity of collagen is of great significance for skin anti-aging and damage repair.

[0004] In recent years, with the rapid development of biotechnology and materials science, the research and application of recombinant collagen has made significant progress. Among them, recombinant type III collagen has become a research hotspot due to its unique biological properties and broad application prospects. Recombinant type III collagen not only has a similar structure and function to natural collagen, but can also be mass-produced and purified through genetic engineering technology, providing new solutions for the field of skin health and beauty.

[0005] In order to solve these problems, researchers have used modern biotechnology to recombinantly optimize the original gene sequence of human type III collagen and obtained a functional protein - recombinant humanized type III collagen. This recombinant collagen is highly similar to the body's own collagen, has better biocompatibility and a lower probability of rejection.

[0006] In this regard, the inventors proposed a preparation method based on recombinant type III collagen to solve the above problems. Summary of the invention

[0007] The object of the present invention is to provide a preparation method based on recombinant type III collagen to solve the problems raised in the above background technology.

[0008] To achieve the above object, the present invention provides the following technical solutions:

[0009] A preparation method based on recombinant type III collagen, comprising the following steps:

[0010] S1. Synthesize gene fragments, including designing corresponding DNA sequences, gene synthesis and sequence verification;

[0011] S2, constructing expression vectors, including vector selection, enzyme digestion and ligation, and transformation and screening;

[0012] S3, protein expression, including pre-culture and induced expression;

[0013] S4, protein extraction and purification, including cell collection and lysis, His tag purification and further purification;

[0014] S5. Quality testing and confirmation, including Western blotting and polyacrylamide gel electrophoresis, mass spectrometry analysis, and functional testing.

[0015] Preferably, the corresponding DNA sequence designed in S1 comprises a sequence encoding 6 histidine His tags, followed by a GPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGER sequence repeated 9 times, based on the repeating sequence of the target amino acid sequence HHHHHGPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGER, to synthesize the DNA sequence of human type III collagen a1 chain;

[0016] The gene synthesis uses commercial gene synthesis services, including Integrated DNA Technologies or GenScript, and Nde I and Hind III restriction endonuclease recognition sites are added during the gene synthesis process for subsequent cloning operations;

[0017] After the synthesis is completed, the sequence verification is performed to verify the accuracy of the DNA sequence.

[0018] Preferably, in S2, an Escherichia coli expression vector pET-30b(+) with a T7 promoter and a His tag sequence is selected, and two restriction endonucleases, Nco I and Hind III, are used to digest the vector and the target gene fragment so that the two produce compatible ends, and then the target gene fragment is connected to the vector by DNA ligase, and the recombinant plasmid is introduced into the Escherichia coli cells by heat shock method or electroporation method, and the transformed cells are spread on a selective culture medium containing the antibiotic kanamycin to screen out colonies containing the recombinant plasmid.

[0019] Preferably, the pre-culture in S3 induces the expression of recombinant type III collagen in the successfully transformed Escherichia coli strain, inoculates a single transformed colony in a liquid culture medium, and cultures at 37° C. overnight;

[0020] The induced expression is to inoculate the pre-culture solution into a fresh culture medium, culture until OD600 reaches 0.6-0.8, then add isopropyl-β-D-thiogalactoside (IPTG) to induce protein expression, and induce expression at 16-37°C for 4-10 hours or overnight.

[0021] Preferably, the cell collection and lysis in S4 comprises collecting the cells by centrifugation, and breaking the cells using a lysis buffer and ultrasound or a high-pressure crusher to release the protein;

[0022] The His tag purification uses a nickel ion affinity chromatography column (Ni-NTA) to purify recombinant type III collagen containing a His tag, and the specific steps include:

[0023] The lysate was passed through a Ni-NTA chromatography column;

[0024] Nonspecifically bound proteins were removed with wash buffer;

[0025] Elute the target protein with elution buffer and imidazole;

[0026] The further purification further purifies the protein by gel filtration chromatography or ion exchange chromatography to obtain recombinant type III collagen with higher purity.

[0027] Preferably, the protein purity and molecular weight are detected by Western blotting and polyacrylamide gel electrophoresis as described in S5 to confirm the presence of the His tag;

[0028] The mass spectrometry analysis confirms the amino acid sequence of the protein;

[0029] The functional test is carried out by cell experiment and biological activity test to confirm the biological function of recombinant type III collagen.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] (1) The recombinant type III collagen in the present invention can enhance the activity of fibroblasts and promote cell metabolism. The recombinant type III collagen can scavenge oxygen free radicals (ROS) and reduce the damage of oxidative stress to cells. By reducing the level of ROS, it protects skin cells from oxidative damage and reduces the skin pigmentation and spot formation caused by free radicals.

[0032] (2) The recombinant type III collagen of the present invention has the ability to specifically bind to integrins, promote the proliferation of fibroblasts and wound healing. The recombinant type III collagen can specifically bind to integrins, activate downstream signaling pathways, promote the proliferation and migration of fibroblasts, and accelerate the healing of skin wounds and tissue repair by promoting the proliferation of fibroblasts and the synthesis of collagen.

[0033] (3) The recombinant type III collagen of the present invention can inhibit the activity and expression of matrix metalloproteinases (MMPs) and promote the formation of new collagen. The recombinant type III collagen can inhibit the activity and expression of MMP-1 and MMP-9, thereby reducing the degradation of collagen, while promoting the synthesis of new collagen and enhancing the elasticity and firmness of the skin. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The present invention is a flow chart of a preparation method based on recombinant type III collagen. DETAILED DESCRIPTION

[0035] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0036] Embodiment 1:

[0037] See also Figure 1 As shown, a preparation method based on recombinant type III collagen comprises the following steps:

[0038] S1. Synthesize gene fragments, including designing corresponding DNA sequences, gene synthesis and sequence verification;

[0039] S2, constructing expression vectors, including vector selection, enzyme digestion and ligation, and transformation and screening;

[0040] S3, protein expression, including pre-culture and induced expression;

[0041] S4, protein extraction and purification, including cell collection and lysis, His tag purification and further purification;

[0042] S5. Quality testing and confirmation, including Western blotting and polyacrylamide gel electrophoresis, mass spectrometry analysis, and functional testing.

[0043] Specifically, the corresponding DNA sequence is designed in S1, and according to the repeating sequence of the target amino acid sequence HHHHHGPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGER, a sequence encoding 6 histidine H is tags is included, followed by a GPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGER sequence repeated 9 times, to synthesize the DNA sequence of the a1 chain of human type III collagen;

[0044] The gene synthesis uses commercial gene synthesis services, including Integrated DNA Technologies or GenScript, and NdeI and HindIII restriction endonuclease recognition sites are added during the gene synthesis process for subsequent cloning operations;

[0045] After the synthesis is completed, the sequence verification is performed to verify the accuracy of the DNA sequence.

[0046] Specifically, in S2, an Escherichia coli expression vector pET-30b(+) with a T7 promoter and a His tag sequence is selected, and two restriction endonucleases, NdeI and Hind III, are used to digest the vector and the target gene fragment. The digestion reaction is carried out at 37°C for 1 hour, and the ligation reaction is carried out with T4 DNA ligase at 16°C overnight to produce compatible ends for the two. The target gene fragment is then connected to the vector by DNA ligase, and the recombinant plasmid is introduced into the Escherichia coli cells by a heat shock method at 42°C for 45 seconds. The transformed cells are spread on an LB medium containing 50 μg / mL of the antibiotic kanamycin, and colonies containing the recombinant plasmid are screened.

[0047] Specifically, pre-culture in S3 induced the expression of recombinant type III collagen in the successfully transformed E. coli strain, and a single transformed colony was inoculated in LB medium with 50 μg / mL kanamycin and cultured at 37°C overnight;

[0048] The induced expression was inoculated into fresh culture medium at a ratio of 1:100, and the overnight culture was inoculated into fresh LB culture medium and cultured until OD600 reached 0.6-0.8, and then isopropyl-β-D-thiogalactoside IPTG was added to induce protein expression at a final concentration of 0.5 mM and an induction temperature of 16°C overnight.

[0049] Specifically, the cell collection and lysis described in S4 is to collect the cells by centrifugation, the centrifugation conditions are 4°C, 6000rpm, 15 minutes, using 50mM Tris-HCl (pH 8.0), 300mM NaCl, 10mM imidazole lysis buffer and ultrasonication to disrupt the cells, the ultrasonication conditions are ice bath, 30 seconds interval, 20 minutes, to release the protein;

[0050] The His tag purification uses a nickel ion affinity chromatography column (Ni-NTA) to purify recombinant type III collagen containing a His tag, and the specific steps include:

[0051] The lysate was passed through a Ni-NTA chromatography column;

[0052] Nonspecifically bound proteins were removed with wash buffer;

[0053] Elute the target protein with elution buffer and imidazole;

[0054] in:

[0055] Chromatography column: Ni-NTA affinity chromatography column

[0056] Equilibration buffer: 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 10 mM imidazo le

[0057] Washing buffer: 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 20 mM imidazolyl

[0058] Elution buffer: 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 250 mM imidazo le

[0059] Further purification The protein is further purified by gel filtration chromatography or ion exchange chromatography to obtain higher purity recombinant type III collagen.

[0060] Gel filtration chromatography: Superdex 200 column

[0061] Buffer: PBS (pH 7.4).

[0062] Specifically, the purity and molecular weight of the protein were detected by Western blotting and polyacrylamide gel electrophoresis as described in S5 to confirm the presence of the His tag;

[0063] The gel concentration was 12%, the protein loading amount was 20 μg, and the detection antibody was anti-His tag antibody, diluted 1:1000.

[0064] The mass spectrometry analysis confirms the amino acid sequence of the protein, using MALDI-TOF or LC-MS / MS, and sends the protein to a mass spectrometry center for analysis after enzyme digestion;

[0065] The functional test is carried out by cell experiment and biological activity test to confirm the biological function of recombinant type III collagen;

[0066] Cell experiments Human skin fibroblasts were cultured and cell proliferation was detected using MTT or CCK-8;

[0067] The biological activity test was as follows: MMPs activity, using ELISA kit to detect the expression levels of MMP-1 and MMP-9.

[0068] The prepared recombinant type III collagen was tested as follows:

[0069] 1. Cell experiments

[0070] Antioxidant activity test

[0071] step:

[0072] Cell culture: Human skin fibroblasts (HFF-1) were cultured in DMEM medium containing 10% fetal bovine serum (FBS).

[0073] Treat cells: Inoculate cells into 96-well plates and culture until the cells are about 80% confluent. Then add different concentrations of recombinant type III collagen (0.1, 1, 10 μg / mL) and set up positive controls (such as vitamin C) and blank controls.

[0074] Oxidative stress induction: Add 500 μM hydrogen peroxide (H2O2) and incubate for 2 hours.

[0075] ROS detection: The DCFH-DA probe was used to detect the intracellular reactive oxygen species (ROS) level, and the fluorescence intensity was read by a fluorescence microplate reader (Ex / Em=488 / 525 nm).

[0076] The experimental data are shown in Table 1 below:

[0077]

[0078] Table 1

[0079] Fibroblast proliferation assay

[0080] step:

[0081] Cell culture: Same as above, using HFF-1 cells.

[0082] Treat cells: Inoculate cells into 96-well plates and culture until the cells are about 80% confluent. Then add different concentrations of recombinant type III collagen (0.1, 1, 10 μg / mL) and set up positive controls (such as EGF) and blank controls.

[0083] Proliferation detection: After 24 hours of incubation, cell proliferation was detected using MTT reagent and the absorbance at 570 nm was recorded.

[0084] The experimental data are shown in Table 2 below:

[0085]

[0086] Table 2

[0087] MMPs activity inhibition test

[0088] step:

[0089] Cell culture: Same as above, using HFF-1 cells.

[0090] Treat cells: Inoculate cells into 6-well plates and culture until the cells are about 80% confluent. Then add different concentrations of recombinant type III collagen (0.1, 1, 10 μg / mL) and set up positive controls (such as TIMP-1) and blank controls.

[0091] MMPs detection: ELISA kits were used to detect the levels of MMP-1 and MMP-9 in the cell culture supernatant.

[0092] The experimental data are shown in Table 3 below:

[0093]

[0094]

[0095] Table 3

[0096] 2. Animal Experiments

[0097] Skin repair test

[0098] step:

[0099] Model establishment: Skin injuries with a diameter of approximately 5 mm were made on the back of mice.

[0100] Treatment: Creams containing different concentrations of recombinant type III collagen (0.1, 1, 10 μg / mL) were applied respectively, the positive control group was applied with cream containing EGF, and the blank control group was applied with basic cream.

[0101] Observation and Record: Observe and record the wound healing status every day until the wound is completely healed.

[0102] The experimental data are shown in Table 4 below:

[0103]

[0104] Table 4

[0105] 3. Human trials

[0106] Skin radiance and pigmentation change test

[0107] step:

[0108] Volunteer recruitment: Recruit 30 female volunteers aged 18-45 years with an even distribution of skin types.

[0109] Grouping: The subjects were randomly divided into three groups, with 10 people in each group. They were treated with cosmetics containing different concentrations of recombinant type III collagen (1, 5, 10 μg / mL), and a blank control group was used as a benchmark.

[0110] Directions: Apply to face every morning and evening for 8 weeks.

[0111] Skin analysis: Use the Visia skin analysis system to test skin radiance, number and area of ​​spots every 2 weeks.

[0112] The experimental data are shown in Table 5 below:

[0113] Skin glossiness score

[0114]

[0115] Table 5

[0116] From the above, we can see that through the data of the above-mentioned cell experiments, animal experiments and human trials, it can be proved that recombinant type III collagen has significant antioxidant activity, promotes fibroblast proliferation, inhibits matrix metalloproteinase activity, accelerates skin healing, improves skin gloss, and reduces the number and area of ​​spots.

[0117] From the above, we can see that recombinant type III collagen can enhance the activity of fibroblasts and promote cell metabolism. Recombinant type III collagen can remove oxygen free radicals (ROS) and reduce the damage to cells caused by oxidative stress. By reducing the level of ROS, skin cells are protected from oxidative damage and the formation of skin pigmentation and spots caused by free radicals is reduced.

[0118] It specifically binds to integrins, promotes fibroblast proliferation and wound healing. Recombinant type III collagen can specifically bind to integrins, activate downstream signaling pathways, promote fibroblast proliferation and migration, and accelerate skin wound healing and tissue repair by promoting fibroblast proliferation and collagen synthesis.

[0119] Inhibit the activity and expression of matrix metalloproteinases (MMPs) and promote the formation of new collagen. Recombinant type III collagen can inhibit the activity and expression of MMP-1 and MMP-9, thereby reducing the degradation of collagen, while promoting the synthesis of new collagen and enhancing the elasticity and firmness of the skin.

[0120] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "examples", "specific examples" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.

[0121] In the drawings of the embodiments disclosed in the present invention, only the structures related to the embodiments disclosed in the present invention are involved, and other structures can refer to the general design. In the absence of conflict, the same embodiment and different embodiments of the present invention can be combined with each other.

[0122] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for preparing recombinant type III collagen, It is characterized in that The following steps are involved: S1. Synthesize gene fragments, including designing corresponding DNA sequences, gene synthesis and sequence verification; S2, constructing expression vectors, including vector selection, enzyme digestion and ligation, and transformation and screening; S3, protein expression, including pre-culture and induced expression; S4, protein extraction and purification, including cell collection and lysis, His tag purification and further purification; S5. Quality testing and confirmation, including Western blotting and polyacrylamide gel electrophoresis, mass spectrometry analysis, and functional testing.

2. A preparation method based on recombinant type III collagen according to claim 1, Features: The corresponding DNA sequence was designed in S1, and the DNA sequence of the human type III collagen a1 chain was synthesized according to the repeating sequence of the target amino acid sequence HHHHHGPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGER, which contained a sequence encoding 6 histidine His tags, followed by a GPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGER sequence repeated 9 times; The gene synthesis uses commercial gene synthesis services, including Integrated DNA Technologies or GenScript, to add NdeI and HindIII restriction endonuclease recognition sites during the gene synthesis process for subsequent cloning operations; After the synthesis is completed, the sequence verification is performed to verify the accuracy of the DNA sequence.

3. A preparation method based on recombinant type III collagen according to claim 1, Features: In S2, the Escherichia coli expression vector pET-30b(+) with a T7 promoter and a His tag sequence is selected, and two restriction endonucleases, NdeI and HindIII, are used to digest the vector and the target gene fragment so that the two produce compatible ends. The target gene fragment is then connected to the vector using DNA ligase, and the recombinant plasmid is introduced into the Escherichia coli cells using the heat shock method or the electroporation method. The transformed cells are spread on a selective culture medium containing the antibiotic kanamycin, and colonies containing the recombinant plasmid are screened.

4. A preparation method based on recombinant type III collagen according to claim 1, Features: Pre-culture in S3 was used to induce the expression of recombinant type III collagen in the successfully transformed E. coli strain, and a single transformed colony was inoculated into liquid culture medium and cultured at 37°C overnight; The induction expression is to inoculate the pre-culture solution into a fresh culture medium, culture until OD600 reaches 0.6-0.8, then add isopropyl-β-D-thiogalactoside IPTG to induce protein expression, induce for 4-6 hours or overnight and induce expression.

5. A preparation method based on recombinant type III collagen according to claim 1, Features: The cell collection and lysis described in S4 are performed by centrifugation to collect the cells, and the cells are broken using a lysis buffer and ultrasound or a high-pressure crusher to release the protein; The His tag purification uses a nickel ion affinity chromatography column (Ni-NTA) to purify recombinant type III collagen containing a His tag, and the specific steps include: The lysate was passed through a Ni-NTA chromatography column; Nonspecifically bound proteins were removed with wash buffer; Elute the target protein with elution buffer and imidazole; The further purification further purifies the protein by gel filtration chromatography or ion exchange chromatography to obtain recombinant type III collagen with higher purity.

6. A preparation method based on recombinant type III collagen according to claim 1, Features: The purity and molecular weight of the protein were checked by Western blotting and polyacrylamide gel electrophoresis as described in S5, and the presence of the His tag was confirmed; The mass spectrometry analysis confirms the amino acid sequence of the protein; The functional test is carried out by cell experiment and biological activity test to confirm the biological function of recombinant type III collagen.

Citation Information

Cited By

  • A recombinant human type III collagen and its preparation method and application

    CN119735668A

  • Recombinant collagen with enhanced skin regeneration ability, preparation method and application thereof

    CN119775394A

  • High-efficiency expression and purification method of recombinant type IV collagen and application of recombinant type IV collagen in cosmetics

    CN119859180A

  • Collagen purification method based on fluorescence tracing and non-chromatographic chromatography technology

    CN120988106A